comparemela.com
Home
Live Updates
RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögrens Syndrome : comparemela.com
RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
/PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced significant...
Related Keywords
Peking ,
Beijing ,
China ,
United States ,
Zhang Hong ,
Shaanxi ,
Yantai ,
Shandong ,
Jianmin Fang ,
Zeng Xiaofeng ,
Remegen Co Ltd ,
Union Medical College Hospital ,
National Medical Products Administration ,
Prnewswire Remegen Co ,
Remegen Co ,
University First Hospital ,
Professor Zhang Hong ,
Peking University First ,
Professor Zeng Xiaofeng ,
Peking Union Medical College ,
Multidimensional Fatigue Inventory ,
comparemela.com © 2020. All Rights Reserved.